Literature DB >> 26664503

CUA guidelines on the management of non-muscle invasive bladder cancer.

Wassim Kassouf1, Samer L Traboulsi1, Girish S Kulkarni2, Rodney H Breau3, Alexandre Zlotta2, Andrew Fairey4, Alan So5, Louis Lacombe6, Ricardo Rendon7, Armen G Aprikian1, D Robert Siemens8, Jonathan I Izawa9, Peter Black5.   

Abstract

Entities:  

Year:  2015        PMID： 26664503      PMCID： PMC4662433          DOI： 10.5489/cuaj.3320

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  161 in total

1.  What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?

Authors:  A R Zlotta; J P van Vooren; K Huygen; A Drowart; M Decock; M Pirson; F Jurion; K Palfliet; O Denis; J Simon; C C Schulman
Journal:  Eur Urol       Date:  2000-04       Impact factor: 20.096

Review 2.  Immunotherapy of bladder cancer.

Authors:  U O Nseyo; D L Lamm
Journal:  Semin Surg Oncol       Date:  1997 Sep-Oct

Review 3.  Natural history of superficial bladder cancer. Prognostic features and long-term disease course.

Authors:  N M Heney
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

4.  Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.

Authors:  Marco Racioppi; Angelo Porreca; Nazario Foschi; Giampaolo Delicato; Antonio Destito; Alessandro D'Addessi
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

5.  Defining bacillus Calmette-Guerin refractory superficial bladder tumors.

Authors:  Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

6.  Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.

Authors:  Timothy O'Brien; Eleanor Ray; Kathryn Chatterton; Muhammad Shamim Khan; Ashish Chandra; Kay Thomas
Journal:  BJU Int       Date:  2013-12       Impact factor: 5.588

7.  Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?

Authors:  Bogdan Geavlete; Razvan Multescu; Dragos Georgescu; Marian Jecu; Florin Stanescu; Petrisor Geavlete
Journal:  BJU Int       Date:  2011-06-28       Impact factor: 5.588

Review 8.  Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.

Authors:  Michael Rink; Marko Babjuk; James W F Catto; Patrice Jichlinski; Shahrokh F Shariat; Arnulf Stenzl; Herbert Stepp; Dirk Zaak; J Alfred Witjes
Journal:  Eur Urol       Date:  2013-07-19       Impact factor: 20.096

9.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

Review 10.  Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.

Authors:  D L Lamm; D R Riggs; C L Traynelis; U O Nseyo
Journal:  J Urol       Date:  1995-05       Impact factor: 7.450
View more
  24 in total

Review 1.  Genomic Subtyping in Bladder Cancer.

Authors:  Tuomas Jalanko; Joep J de Jong; Ewan A Gibb; Roland Seiler; Peter C Black
Journal:  Curr Urol Rep       Date:  2020-03-13       Impact factor: 3.092

2.  Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.

Authors:  Michael J Metcalfe; James E Ferguson; Roger Li; Lianchun Xiao; Charles C Guo; Bogdan A Czerniak; Arlene Siefker-Radtke; Shanna M Pretzsch; Neema Navai; David J McConkey; Ashish M Kamat; Mathew Campbell; Colin Dinney
Journal:  Eur Urol Focus       Date:  2017-07-13

3.  Poster Exhibit 2: Non-prostate Genitourinary Cancers.

Authors: 
Journal:  Can Urol Assoc J       Date:  2021-06       Impact factor: 1.862

4.  Mycotic aneurysm formation after bacillus Calmette-Guérin instillation for recurrent bladder cancer.

Authors:  Sagar Rohailla; Abhijat Kitchlu; Mark Wheatcroft; Fahad Razak
Journal:  CMAJ       Date:  2018-04-16       Impact factor: 8.262

5.  Are there differences among bacillus Calmette-Guérin (BCG) strains regarding their clinical efficacy in the treatment of non-muscleinvasive bladder cancer? The jury is still out but the answer is likely no.

Authors:  Guan Hee Tan; Cynthia Kuk; Alexandre R Zlotta
Journal:  Can Urol Assoc J       Date:  2019-07-23       Impact factor: 1.862

6.  Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.

Authors:  Zachary Klaassen; Kathy Li; Wassim Kassouf; Peter C Black; Alice Dragomir; Girish S Kulkarni
Journal:  Can Urol Assoc J       Date:  2017-06       Impact factor: 1.862

7.  Pathology review impacts clinical management of patients with T1-T2 bladder cancer.

Authors:  Samer L Traboulsi; Fadi Brimo; Yutong Yang; Chelsea Maedler; Noémie Prévost; Simon Tanguay; Armen G Aprikian; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2017-06       Impact factor: 1.862

Review 8.  Implementing risk-aligned bladder cancer surveillance care.

Authors:  Florian R Schroeck; Nicholas Smith; Jeremy B Shelton
Journal:  Urol Oncol       Date:  2018-02-13       Impact factor: 3.498

9.  Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.

Authors:  Kiran Tripathi; Apul Goel; Atin Singhai; Minal Garg
Journal:  Mol Biol Rep       Date:  2021-02-23       Impact factor: 2.316

10.  Bladder cancer presenting with acrometastases: a different cause of foot pain.

Authors:  João Matos; Ilaria Mussetto; Raffaella Podestà; Daria Schettini; Nicoletta Gandolfo
Journal:  Skeletal Radiol       Date:  2018-02-01       Impact factor: 2.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.